The AML-defining recurrent genetic alterations, involving PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11, can now be detected through targeted RNA sequencing, which may further aid in discriminating between AML and MDS in equivocal blast-count cutoff threshold. The gene discussed is RARA; the disease is acute myeloid leukemia.